Does the typical 6-month regimen for pulmonary tuberculosis have any advantages over the four-month high-dose rifampicin regimen?

Published Date: 25 Aug 2023

UK: Four-month high-dose rifampicin regimens had few side effects but failed to pass the noninferiority test when compared to the.

Read Full News

Latest News

Air Trapping Predicts Pneumothorax After BLVR

Noninvasive analysis can help patients avoid in-hospital post-procedure monitoring.

Sanofi Says Rare Lung Disease Drug Outperforms Standard Care in Trial

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Integrating Multidisciplinary Insights Into Treatment Decisions in Resectable NSCLC

Integrating Multidisciplinary Insights Into Treatment Decisions in Resectable NSCLC

Optimizing HER2 Assessment and Treatment in Advanced NSCLC: From Guidelines to the Clinic

Optimizing HER2 Assessment and Treatment in Advanced NSCLC: From Guidelines to the Clinic

Managing Treatment-Related Adverse Events Associated With Novel Immunotherapy-Based Combination Approaches in Advanced NSCLC

Managing Treatment-Related Adverse Events Associated With Novel Immunotherapy-Based Combination Approaches in Advanced NSCLC

Targeted and Immunotherapy-Based Combination Approaches in Advanced NSCLC: Second-Line and Beyond

Targeted and Immunotherapy-Based Combination Approaches in Advanced NSCLC: Second-Line and Beyond

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Noninvasive analysis can help patients avoid in-hospital post-procedure monitoring.

(Corrects executive's name from Alaa Ahmed to Alaa Hamed in paragraphs 7 and 8)

Integrating Multidisciplinary Insights Into Treatment Decisions in Resectable NSCLC

Optimizing HER2 Assessment and Treatment in Advanced NSCLC: From Guidelines to the Clinic

Managing Treatment-Related Adverse Events Associated With Novel Immunotherapy-Based Combination Approaches in Advanced NSCLC

Targeted and Immunotherapy-Based Combination Approaches in Advanced NSCLC: Second-Line and Beyond

News All Time

Doc Gave Patients Recalled CPAPs 'Fixed' by His Own Children

Sleep medicine specialist was sentenced to a year in prison and will pay $350K in restitution

Cooking and Dementia Risk; High-Dose vs Standard-Dose Flu Shot

Also in TTHealthWatch: replacing the aortic valve in asymptomatic people

Alzheimer's Risk May Be Influenced by Flu Shots

High-dose vaccine tied to roughly 20% lower risk of Alzheimer's dementia

Here's How Many Doctors and Nurses Are Getting Flu or COVID Shots

Nurses in particular do not seem to be fans of the COVID-19 vaccine

Trump: 'It Was Me as a Doctor'; Lululemon PFAS Probe; Dick Vitale's Fifth Cancer Dx

Health news and commentary gathered by MedPage Today staff

Quiz Time: How Are Flu Shots and Alzheimer's Linked?

You passed medical training, now see if you can pass our weekly quiz

Doc Detained by Border Patrol; Lady Gaga Sick, Cancels Show; Sexy Chocolate Recall

Health news and commentary gathered by MedPage Today staff

Amoxicillin Alone Holds Up for Acute Sinusitis

Observational study supports efficacy, safety compared with amoxicillin-clavulanate

Novel KRAS Drug Shows 'Excellent' Efficacy in Tough-to-Treat Lung Cancer

Zoldonrasib ideal for further evaluation in KRAS G12D-mutant disease, expert says

Early Lung Cancer Data Show Why FDA Approved HER2 Agent in First-Line

Zongertinib in phase I trial showed sustained efficacy in aggressive disease

Undetected TB May Be Lurking in U.S. Hospitals, Ultrasensitive Assay Suggests

Findings of TB DNA will require larger studies to confirm clinical relevance, says researcher

Congresswoman Tied to COVID Fraud Resigns; DOD Ends Flu Vax Mandate; USPSTF Overhaul

Health news and commentary gathered by MedPage Today staff

If It's COVID, Paxlovid? Studies Suggest a Rethink These Days

In a post-pandemic landscape, the drug didn't top usual care at stopping hospitalization, death

Bronchial Casts: An Unusual Complication of Wildfire Smoke Inhalation

Case is a "graphic demonstration" of emergent, severe impacts of forest fires for everyday people

Portable Tuberculosis Diagnostic Tool Matched Traditional Tests' Results

The MiniDock MTB could expand access to molecular testing in peripheral health centers

Why Is a Healthy 22-Year-Old Male Suddenly Fainting and Short of Breath?

Careful questioning about patient's recent behaviors gave vital clue

Recommended News For You

Studies point to redlining as a 'perfect storm' for breast cancer

improvements in the treatment of prostate cancer resistant to chemotherapy.

The Benefits of Exercise for Substance Use Disorders.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Q&A: Why adolescents and young adults with cancer are falling behind

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

Recommended Articles For You

An Overview Of Leukemia Cutis: What It Is And How To Treat It 

Understanding Leiomyoma: Causes, Symptoms, and Treatment Options 

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment 

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods

1.

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?

2.

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia

3.

Unveiling the Hidden Mechanisms of Hemolytic Reactions

4.

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics

5.

Understanding Epoetin and Its Role in Treating Chronic Kidney Disease 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- Q&A Session to Close the Gap

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot